Medical Company Granted FDA Clearance For Netherton Syndrome Clinical Trials

Quoin Pharmaceuticals Receives FDA Clearance to Recruit Teenagers in Netherton Syndrome Clinical Trials.

All information provided in this article is accurate, factual, and up-to-date.

In a significant development that could potentially alter the trajectory of Netherton Syndrome treatment, Quoin Pharmaceuticals (NASDAQ: QNRX) has received clearance from the U.S. Food and Drug Administration (FDA) to include teenage subjects in their ongoing clinical studies.…